Monopar Therapeutics MNPR Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's total liabilities & equity?
- Monopar Therapeutics (MNPR) reported total liabilities & equity of $137.98M in Q1 2026.
- How has Monopar Therapeutics's total liabilities & equity changed year-over-year?
- Monopar Therapeutics's total liabilities & equity increased by 150.5% year-over-year, from $55.09M to $137.98M.
- What is the long-term trend for Monopar Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total liabilities & equity has grown at a 52.8% compound annual growth rate (CAGR), from $16.87M to $140.72M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.